In yesterday’s Wall Street session, Envista Holdings Corporation (NYSE:NVST) shares traded at $34.42, down -1.52% from the previous session.
As of this writing, 10 analysts cover Envista Holdings Corporation (NYSE:NVST). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $46.00 and a low of $38.00, we find $42.00. Given the previous closing price of $34.95, this indicates a potential upside of 20.17 percent. NVST stock price is now 1.87% away from the 50-day moving average and -3.87% away from the 200-day moving average. The market capitalization of the company currently stands at $5.74B.
There are 1 analysts who have given it a hold rating, whereas 9 have given it a buy rating. Brokers who have rated the stock have averaged $42.78 as their price target over the next twelve months.
With the price target enhanced from $40 to $46, Piper Sandler Upgraded its rating from Neutral to Overweight for Envista Holdings Corporation (NYSE: NVST).
In other news, Yu Howard H, Chief Financial Officer sold 10,016 shares of the company’s stock on Feb 28. The stock was sold for $379,606 at an average price of $37.90. Upon completion of the transaction, the Chief Financial Officer now directly owns 45,865 shares in the company, valued at $1.58 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 17, Chief Financial Officer Yu Howard H sold 657 shares of the business’s stock. A total of $24,013 was realized by selling the stock at an average price of $36.55. This leaves the insider owning 51,106 shares of the company worth $1.76 million. Insiders disposed of 94,753 shares of company stock worth roughly $3.26 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NVST stock. A new stake in Envista Holdings Corporation shares was purchased by EMINENCE CAPITAL, LP during the first quarter worth $81,315,000. MARSHALL WACE, LLP invested $19,548,000 in shares of NVST during the first quarter. In the first quarter, ADAGE CAPITAL PARTNERS GP, L.L.C. acquired a new stake in Envista Holdings Corporation valued at approximately $10,232,000. DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT acquired a new stake in NVST for approximately $10,015,000. IMPAX ASSET MANAGEMENT GROUP PLC purchased a new stake in NVST valued at around $8,089,000 in the second quarter. In total, there are 448 active investors with 115.84% ownership of the company’s stock.
Tuesday morning saw Envista Holdings Corporation (NYSE: NVST) opened at $34.96. During the past 12 months, Envista Holdings Corporation has had a low of $31.20 and a high of $43.29. As of last week, the company has a debt-to-equity ratio of 0.32, a current ratio of 1.30, and a quick ratio of 1.00. According to the stock market information, the enterprise value for the company is $6.52B, which is based on a 28.78 price-to-earnings ratio, a 2.74 price-to-earnings-growth ratio, and a beta of 1.41. The fifty day moving average price for NVST is $33.82 and a two-hundred day moving average price translates $35.81 for the stock.
The latest earnings results from Envista Holdings Corporation (NYSE: NVST) was released for Jun, 2023. According to the Medical Instruments & Supplies Company, earnings per share came in at $0.43, beating analysts’ expectations of $0.41 by 0.02. This compares to $0.01 EPS in the same period last year. The company reported revenue of $662.4 million for the quarter, compared to $645.8 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2.57 percent. For the current quarter, analysts expect NVST to generate $649.88M in revenue.
Envista Holdings Corporation(NVST) Company Profile
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists, and periodontists; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant for treatment planning of dental implants; DTX Studio Lab for prosthetics treatment planning; and DTX Studio Clinic, a software package offered with its imaging devices. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related consumables; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
